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Clopidogrel Is Not Associated With Major Bleeding Complications
During Peripheral Arterial Surgery
David H. Stone, MD, Philip P. Goodney, MD, Brian W. Nolan, MD,
Andres Schanzer, MD, Donald S. Likosky, PhD, Julie Adams, MD, William
Tanski, MD, Daniel B. Walsh, MD, and Jack L. Cronenwett, MD, Dart-
mouth-HitchcockMedical Center, Lebanon, NH,Worcester, MA, Burling-
ton, VT, and Concord, NH
Objectives: Persistent variation in practice surrounds preoperative
clopidogrel (Plavix) management at the time of vascular surgery. Although
some surgeons preferentially discontinue clopidogrel, citing a perceived risk
of perioperative bleeding, others will proceed with surgery in patients taking
clopidogrel. The purpose of this study was to determine whether preopera-
tive clopidogrel use was associated with significant bleeding complications
during peripheral arterial surgery.
Methods:We reviewed a prospective regional vascular surgery registry
(VSGNE) of 66 surgeons from 12 centers in New England from 2003-
2009. Preoperative clopidogrel use 48 hours of surgery was analyzed
among patients undergoing carotid endarterectomy (CEA), lower extremity
bypass (LEB), endovascular abdominal aortic aneurysm repair (EVAR), and
open abdominal aortic aneurysm (AAA) repair. End points included postoper-
ative bleeding requiring reoperation as well as blood transfusion. Statistical
analysis was performed using Fisher exact and Wilcoxon rank sum tests.
Results:During the study interval, 5264 patients underwent CEA, 2883
underwent LEB, 1153 underwent EVAR, and 1330 underwent open AAA
repair, in whom 16.2%, 9.0%, 6.9%, and 4.6% were maintained on clopidogrel,
respectively. Reoperation for bleeding was not significantly different among
patients taking clopidogrel vs patients not taking clopidogrel at the time of
surgery across all operation categories. There was no difference in the incidence
of transfusion among treatment groups for all types of operation (Table). In
addition, among patients who did require transfusion, there was no significant
difference between clopidogrel-treated and non-clopidogrel-treated groups in
the mean units of packed red blood cells required (Table).
Conclusions: Patients undergoing peripheral arterial surgery in whom clo-
pidogrel was continued did not have significant bleeding complications compared
with patients not on clopidogrel. These data provide reassurance that clopidogrel
can safely be continued preoperatively in patients with important indications for its
use, such as symptomatic carotid disease or recent drug-eluting cardiac stents.
Standardized Angioplasty and Stenting Techniques for SFA-Popliteal
TASC C and D Lesions Improve Outcomes: A Prospective Evaluation
ManishMehta, MDMPH, Philip S. K. Paty, MD, Sean P. Roddy, MD, Paul
B. Kreienberg, MD, Yaron Sternbach, MD, John B. Taggert, MD, Kathleen
J. Ozsvath, MD, John W. Byrne, MD, Benjamin B. Chang, MD, Dhiraj M.
Shah,MD, and R.ClementDarling III,MD,TheVascularGroup, Albany,NY
Objectives: This study evaluated whether standardization of superficial
femoral-above knee popliteal artery (SFA-AK-PA) percutaneous angioplasty
and stenting (PTAS) improves outcomes when treating TASC C and D lesions
Methods: From 2004-2009, 698 patients with symptomatic infraingui-
nal SFA-AK-PA TASC-C/D lesions who underwent PTAS or bypass were
divided into three groups: standardized PTAS technique (n  213, 31%) vs
nonstandardized PTAS technique (n  179, 26%) vs Fem-AK-Pop PTFE
bypass (n 306, 43%). The standardized technique included (1) initial subin-
timal angioplasty with higher balloon pressures (range, 20-25 atm), (2) 20%
balloon oversizing, (3) routine use of self-expanding stents after angioplasty, (4)
minimum stent-stent overlap of1 cm, and (5) treatment of all moderate and
severe SFA/popliteal occlusive disease. The nonstandardized technique and
802Fem-AK-Pop PTFE bypass included most routine approaches used today, not
adhering to the standardization. Patients were followed-up at 1 month, 3
months, and at 6-month intervals with duplex ultrasound imaging, PVR, and
clinical examination. Data were prospectively collected. The SVS criteria were
used to define patency.
Results: Table
Conclusions: Even with longer lesion lengths, the standardized PTAS
technique for SFA-AK-PA occlusive disease has superior 1-, 2-, and 3-year primary
patency compared with the routine nonstandardized techniques or Fem-AK-Pop
PTFE bypasses. A randomized prospective multicenter trial comparing standard-








Patients, No. (%) 213 (31) 179 (26) 306 (43) .05
Claudication, No.
(%)
126 (59) 93 (52) 116 (38) .05
Rest pain/tissue
loss, No. (%)
87 (41) 86 (48) 190 (62) .05
Lesion length,
mean cm








1 year 95 76 81
2 years 86 64 73




66 (16.8) 66 (16.8) 47 (15.4) NS
Lower Extremity Revascularization (LER) in Young Patients: Have
Endovascular Options Impacted Practice and Outcomes?
Cassius Iyad N. Ochoa Chaar, MD, Steven Leers, MD, Luke Marone, MD,
Jae Cho, Donald T. Baril, MD, Nathan Fernandez, MD, Geetha Jeyabalan,
MD, Robert Y. Rhee, MD, Michel S. Makaroun, MD, and Rabih A. Chaer,
MD, University of Pittsburgh Medical Center, Pittsburgh, Pa
Objectives: This study assessed outcomes and utilization of revascular-
ization options in young patients with premature vascular disease.
Methods: A retrospective comparison of LER outcomes from 2000-
2008 was performed between consecutive patients aged 50 years
(group A) at the time of revascularization and control groups B (51-60
years) and C (60 years) of selected patients with comparable indications
and procedures. Kaplan-Meier curves and logistic regression analyses
were applied to patency, limb salvage, and survival on limb level or
patient level, as indicated.
Results: A total of 409 limbs in 298 patients (Table) were treated for
claudication (44%) or critical limb ischemia (CLI; 56%). Patients in group A
were more likely to be smokers and have a hypercoagulable state but were
less likely to have diabetes and renal failure. Indications for treatment were
comparable among groups, with nearly half of all procedures endovascular in
nature. Two perioperative deaths were both in group C (2%). Mean fol-
low-up was 29 months, with a remarkable 16% of claudicants in group A
progressing to CLI (B: 3.3%, C: 1.7%; P  0.001). Overall, 2-year primary,
primary-assisted, and secondary patency were significantly lower in group
A (51%, 65%, 68%) than in B (58%, 79%, 84%), and C (66%, 81%, 87%;
P  .045, .01, .001). Claudicants in group A, in particular, had lower
patency rates (Fig 1), with an unexpectedly low 2-year limb salvage rate
after intervention of only 90% (Fig 2). Results were more comparable
across groups for CLI. The 2-year freedom from reintervention was
similar among the three groups (A: 81%, B: 79%, C: 84%), irrespective of
the indication for intervention (P  NS). Younger patients had a
significantly higher 3-year survival (A: 90%, B: 85%) compared with
patients aged 60 (C: 71%; P  .005). The 2-year limb salvage rate was
significantly lower in claudicants in group A vs C undergoing endovas-
cular revascularization (P  .002), but not in patients treated with open
revascularization (P  NS). Predictors of loss of primary patency in-
cluded age 50 (P  .003), endovascular revascularization (P  .005),
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Volume 52, Number 3 Abstracts 803and CLI on presentation (P  .002). Age 50 was also an independent
predictor of limb loss compared with age 60 (P  .05).
Conclusion: Endovascular options are commonly being used in young
patients, especially claudicants, but patency rates and outcomes remain very
poor.
Demographic and clinical characteristics by age group
Characteristics 50 years 51-60 years 60 years P
Patient level (n  97) (n  103) (n  98)
Mean SD Mean SD Mean SD
Age at surgery, mean
 SD, y
45  5 56  3 73  8 .001
% (No.) % (No.) % (No.)
Male 57 (55) 65 (67) 63 (62) .44
History
CAD 43 (42) 55 (57) 62 (60) .03
ESRD 6 (6) 19 (20) 13 (13) .02
Hypertension 76 (74) 82 (84) 87 (85) .17
Hypercholesterolemia 58 (56) 64 (66) 69 (60) .28
Diabetes 38 (37) 43 (44) 62 (61) .002
Smoking 83 (80) 79 (81) 62 (61) .003
Hypercoagulable state 16 (15) 5 (5) 3 (2) .004
Limb level (n  139) (n  151) (n  119)
Procedure
Percutaneous 40 (55) 52 (78) 52 (61) .15
Open surgery 57 (79) 46 (69) 47 (57) .15
Hybrid 3 (5) 2 (4) 1 (1) .15
Indication
Claudication 46 (64) 45 (68) 37 (42) .16
Critical limb ischemia 54 (75) 54 (83) 63 (77) .16Comparison of Ultrasound Accelerated Thrombolysis Versus Simple In-
fusion Catheter Directed Thrombolysis for Acute Arterial Thrombosis
Parth S. Shah,MBBSMPH, Anil Hingorani,MD, Enrico Ascher,MD,Uma
Ballehaninna, MBBS, Alexander Shiferson, DO, Natalie Marks, RVT, Kapil
Gopal, MD, Daniel Jung, DO and Theresa Jacobs, PhD, Maimonides
Medical Center, Brooklyn, NY
Objectives: Catheter-directed intra-arterial thrombolysis for acute
peripheral arterial ischemia has become a standard practice for acute
arterial thrombosis. There has been significant amount of literature
published as far as the choice of the thrombolytic agent and injection
techniques. One technique used to accelerate thrombolysis is with the
use of ultrasound imaging (EKOS). We looked at our experience to
compare the outcomes with a simple side-hole infusion catheter (Uni-
fuse) vs EKOS catheters.
Methods: We retrospectively reviewed our data set from January
2006 to August 2008 for all the patients undergoing catheter-directed
thrombolysis for acute lower extremity arterial ischemia. The primary
comparison variables were the duration of thrombolysis and technical
success rate. The technical success rate was defined as complete or nearly
complete clearance of clot burden allowing intervention in form of
percutaneous transluminal angioplasty (PTA) and/or stenting. The data
were also stratified according to the location of the thrombus, complica-
tions, mortality, and limb loss rates. Tissue plasminogen activator (TPA)
was infused at 0.5 to 2.0 mg/h and patients underwent serial angiogra-
phy every 12 to 24 hours.
Results:There were 69 cases of peripheral catheter-directed thrombol-
ysis with the Unifuse catheter and 22 were performed using the EKOS
catheter during the study period. The average duration of thrombolysis was
1.65 days (SD, 0.83) in the Unifuse catheter group vs 1.9 days (SD, 0.92) in
the EKOS catheter group (P  .22). Technical success was achieved in 72%
in the Unifuse group vs in 86% in the EKOS group (P  .31). Ten of 69
(14%) in Unifuse group and 2 of 22 (9%) in the EKOS group had limb loss
(P  .46). Complications were compartment syndrome requiring fas-
ciotomy and bleeding requiring premature cessation of thrombolysis. No
deaths occurred as an immediate result of complications. The complication
rate was 13% in the Unifuse group vs 10% in the EKOS group (P  .46).
Conclusions: There was no statistically significant difference in the
outcomes in catheter-directed thrombolysis in the treatment of acute
arterial ischemia using the Unifuse catheter vs the more expensive EKOS
catheter.
Cryoplasty Offers No Advantage Over Standard Balloon Angioplasty
for the Treatment of In-Stent Restenosis
Susanna H. Shin, Donald Baril, Rabih Chaer, MD, Michel Makaroun, MD,
Robert Rhee, MD, and Luke Marone, MD, UPMC, Pittsburgh, Pa
Objectives: In-stent restenosis is the primary failure mode of endo-
vascular treatment of occlusive disease in the femoropopliteal segment.
Cryoplasty has been proposed to reduce intimal hyperplasia through
induction of apoptosis. We sought to evaluate the efficacy of cryoplasty
for treatment of in-stent restenosis compared with conventional balloon
angioplasty (CBA).
Methods: After IRB approval, a retrospective record review was per-
formed of reinterventions for in-stent restenosis by a single vascular surgery
group at a university hospital. Reinterventions involving cryoplasty and CBA
were evaluated at 1, 3, 6, and 12 months after intervention with duplex
imaging to identify significant recurrent stenosis utilizing established veloc-
ity criteria. Data collected included basic demographic information and
comorbidities as well as time to restenosis. Statistical analysis was performed
using Kaplan-Meier survival curves with the log rank test, Wilcoxon rank
test, and Cox proportional hazards models.
Results: FromDecember 2004 toNovember 2009, 76 reinterventions
were performed using CBA (n  39) or cryoplasty (n  37) for in-stent
restenosis without placement of additional stents. Periprocedural technical
success (30% residual stenosis) was 100% for both groups, with no com-
plications. The two cohorts were statistically similar in mean age, gender
distribution, comorbidities (including active tobacco use), and use of statins,
aspirin, and Plavix. However, the mean lesion length was significantly
longer in the cryoplasty cohort (CBA: 140.9 mm, Cryo: 191.7 mm; P 
.032). The mean time to recurrent stenosis or need for additional
secondary intervention was significantly shorter for the cryoplasty cohort
than for the CBA, 4.09 and 10.79 months, respectively (P  .0001).
Recurrent stenosis-free survival was significantly lower in the cryoplasty
cohort at 3 months (CBA: 96.9%, Cryo: 88.9%) and 6 months (CBA:
84.0%, Cryo: 43.8%; P  .0089).Conclusions: Cryoplasty as a modality for treatment of in-stent steno-
sis in the femoropopliteal segment offers no benefit over CBA.
